SARS-CoV-2 vaccine response in ANCA associated vasculitis patients.

Lauren Floyd,Mohamed E. Elsayed,Tobias Seibt,Anke von Bergwelt-Baildon,Philip Seo,Brendan Antiochos,Sam Kant,Adam Morris,Ajay Dhaygude,Ulf Schönermarck,Duvuru Geetha

Kidney International Reports（2021）

引用 4|浏览9

暂无评分

摘要

The development of COVID-19 vaccines and mass vaccination is a landmark achievement of modern medicine. Management of patients with antineutrophil cytoplasmic autoantibodies–associated vasculitis (AAV) during the pandemic has been challenging. Immunosuppressive medications to control vasculitis are associated with severe COVID-19 infection and may impair immune response to the vaccine.

查看译文

关键词

antineutrophil cytoplasmic autoantibody–associated,vaccine,sars-cov

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要